Evidence map›Paper›PMID 37202916›Full record

ArticleCell cycle (Georgetown, Tex.)2023

Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.

Shan-Shan Yin, Chen Chen, Zhen Liu, Shan-Ling Liu, Jia-Hui Guo, Chao Zhang, Quan-Wu Zhang, Feng-Hou Gao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Shan-Shan YinDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chen ChenClinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Wangfujing, Dongcheng District, Beijing, China.
Zhen LiuDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shan-Ling LiuDepartment of Clinical Laboratory, The First Hospital of Changsha City, Changsha, China.
Jia-Hui GuoDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chao ZhangDepartment of Geriatrics, Shanghai ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Quan-Wu ZhangDepartment of Pathology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Feng-Hou GaoDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Jiao Tong University · CNPeking Union Medical College Hospital · CNShanghai Ninth People's Hospital · CNThe First Hospital of Changsha · CNZhengzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoalantolactone (Iso) is a bioactive lactone isolated from the root of Inula helenium L, which has been reported to have many pharmacological effects. To investigate the role and mechanism of isoalantolactone in chronic myeloid leukemia (CML), we first investigated isoalantolactone's anti-proliferative effects on imatinib-sensitive and imatinib-resistant CML cells by CCK8. Flow cytometry was used to detect isoalantolactone-induced cell apoptosis. Survivin was overexpressed in KBM5 and KBM5

Indexed as

Drug Resistance, NeoplasmLeukemia, Myelogenous, Chronic, BCR-ABL PositiveApoptosisCaspase 3Cell Line, TumorCell ProliferationFusion Proteins, bcr-ablHumansImatinib MesylateRNA, MessengerSesquiterpenesSurvivinUbiquitinsCaspase 3Fusion Proteins, bcr-ablImatinib MesylateisoalantolactoneRNA, MessengerSesquiterpenesSurvivinUbiquitinsBCR-ABLcaspase-3chronic myeloid leukemiaIsoalantolactoneprotein degradationsurvivin

Identifiers

PMID37202916
PMCPMC10281474
OpenAlexW4377092842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.